Christian Hermann Ottensmeier

List of Publications by Year
in descending order

234	38,604	16451 64	2895 190
papers	citations	h-index	g-index

249	249	249	44238
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment. Neuroendocrinology, 2022, 112, 370-383.	2.5	5
2	CD8 Tâ€cellâ€mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	5
3	Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. Melanoma Research, 2022, 32, 103-111.	1.2	8
4	Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis. BMJ Open, 2022, 12, e041961.	1.9	6
5	Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer. , 2022, 10, e003821.		12
6	HIF activation enhances FcÎ³RIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. Journal of Experimental and Clinical Cancer Research, 2022, 41, 131.	8.6	9
7	Changes in Gene Expression Patterns in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Under Chemoradiotherapy Depend on Response. Frontiers in Oncology, 2022, 12, 862694.	2.8	1
8	Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. European Journal of Cancer, 2022, 166, 287-299.	2.8	7
9	CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer. Frontiers in Immunology, 2022, 13, 842653.	4.8	7
10	Intermittent PI3KÎ´ inhibition sustains anti-tumour immunity and curbs irAEs. Nature, 2022, 605, 741-746.	27.8	36
11	Abstract CT213: A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY). Cancer Research, 2022, 82, CT213-CT213.	0.9	1
12	Abstract CT214: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA). Cancer Research, 2022, 82, CT214-CT214.	0.9	1
13	Tissue resident memory T cells (TRM) in primary, metastatic and recurrent head and neck squamous cell carcinoma (HNSCC) tissue. Laryngo- Rhino- Otologie, 2022, , .	0.2	0
14	GewebsansÃssige GedÃchtnis-T-Zellen (TRM) in primÃrem, metastasiertem und rezidivierendem Plattenepithelkarzinom des Kopfes und Halses (HNSCC). Laryngo- Rhino- Otologie, 2022, , .	0.2	0
15	NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.. Journal of Clinical Oncology, 2022, 40, TPS2682-TPS2682.	1.6	1
16	FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).. Journal of Clinical Oncology, 2022, 40, 9510-9510.	1.6	22
17	Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. International Immunopharmacology, 2022, 110, 108985.	3.8	14
18	Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). International Journal of Cancer, 2021, 148, 2023-2035.	5.1	6

#	Article	IF	Citations
19	Melanoma-reactive T cells take up residence. Nature Cancer, 2021, 2, 253-255.	13.2	1
20	An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).. Journal of Clinical Oncology, 2021, 39, TPS9138-TPS9138.	1.6	2
21	Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. Nature Immunology, 2021, 22, 1052-1063.	14.5	61
22	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 2021, 21, 761.	2.6	12
23	Early-Phase Interventional Trials in Oral Cancer Prevention. Cancers, 2021, 13, 3845.	3.7	7
24	Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. Cancers, 2021, 13, 4875.	3.7	7
25	Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2â€“reactive CD8 ⁺ T cells. Science Immunology, 2021, 6, .	11.9	185
26	DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. Frontiers in Immunology, 2021, 12, 763086.	4.8	9
27	Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 1530-1540.	10.7	130
28	COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types. Nature Communications, 2021, 12, 6760.	12.8	32
29	CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer. Cancers, 2020, 12, 2963.	3.7	5
30	Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell, 2020, 183, 1340-1353.e16.	28.9	431
31	M1^{hot}tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. , 2020, 8, e000778.		99
32	HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. Cells, 2020, 9, 2103.	4.1	48
33	CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage. , 2020, 8, e000473.		31
34	Novel players: tissue-resident memory B cells. Blood, 2020, 136, 2722-2723.	1.4	2
35	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
36	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51

#	Article	IF	Citations
37	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 895-904.	10.7	111
38	NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors. Cancer Research, 2020, 80, 1846-1860.	0.9	189
39	Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. Cell Death Discovery, 2020, 6, 54.	4.7	23
40	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. International Journal of Cancer, 2020, 146, 2305-2314.	5.1	44
41	Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC. Frontiers in Oncology, 2020, 10, 591063.	2.8	3
42	Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 ⁺ T Cells. SSRN Electronic Journal, 2020, , 3641939.	0.4	31
43	Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-Î±. ELife, 2020, 9, .	6.0	76
44	Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Research, 2020, 80, CT301-CT301.	0.9	31
45	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. , 2020, , 761-783.		1
46	Abstract PO-039: Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer. , 2020, , .		0
47	Paracrine signalling during ZEB1-mediated epithelialâ€“mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. Cell Death and Differentiation, 2019, 26, 943-957.	11.2	104
48	Autophagy inhibition-mediated epithelialâ€“mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell Death and Disease, 2019, 10, 591.	6.3	107
49	An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing. Scientific Reports, 2019, 9, 9580.	3.3	46
50	Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. Journal of Experimental Medicine, 2019, 216, 2128-2149.	8.5	160
51	HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8+ T-cell Tumor Infiltration in OPSCC. Cancer Immunology Research, 2019, 7, 1202-1213.	3.4	24
52	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2019, 18, 1255-1268.	3.8	45
53	Neoantigen-directed immune escape in lung cancer evolution. Nature, 2019, 567, 479-485.	27.8	639
54	Recent advances in the molecular landscape of lung neuroendocrine tumors. Expert Review of Molecular Diagnostics, 2019, 19, 281-297.	3.1	38

#	Article	IF	Citations
55	Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. OncoImmunology, 2019, 8, e1593810.	4.6	44
56	Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant T _{FH} cells. Science Translational Medicine, 2019, 11, .	12.4	90
57	Importance of the immune system in head and neck cancer. Head and Neck, 2019, 41, 2789-2800.	2.0	28
58	The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis. BMJ Open, 2019, 9, e031531.	1.9	12
59	Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565, 240-245.	27.8	637
60	HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma. British Journal of Cancer, 2019, 120, 356-367.	6.4	41
61	An Optimized Method to Isolate Human Fibroblasts from Tissue for Ex Vivo Analysis. Bio-protocol, 2019, 9, e3440.	0.4	0
62	Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma. , 2019, , .		0
63	Abstract B139: Plant viral particle vaccine induces a potent antitumor response through induction of antigen-specific T-cells and overcoming an immunosuppressive tumor microenvironment. , 2019, , .		0
64	Abstract 3762: Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors. , 2019, , .		0
65	Abstract 1466: Combination immunotherapy successfully control tumor growth in a transgenic mouse model. , 2019, , .		0
66	Abstract 3762: Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors. , 2019, , .		5
67	Real-world use of anti-PD-1 checkpoint inhibitors in the management of non-small cell lung cancer: experience from a large UK teaching hospital. Lung Cancer, 2018, 115, S35.	2.0	0
68	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. OncoImmunology, 2018, 7, e1433516.	4.6	31
69	Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. Journal of Surgical Oncology, 2018, 117, 1170-1178.	1.7	65
70	Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. OncoImmunology, 2018, 7, e1395125.	4.6	26
71	Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model. Cancer Immunology, Immunotherapy, 2018, 67, 627-638.	4.2	28
72	Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. Journal of the National Cancer Institute, 2018, 110, 109-120.	6.3	134

#	Article	IF	Citations
73	CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials, 2018, 19, 233.	1.6	41
74	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell, 2018, 33, 649-663.e4.	16.8	448
75	Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLAâ€Peptide Multimer Staining Assay. Cytometry Part B - Clinical Cytometry, 2018, 94, 342-353.	1.5	12
76	BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY. Retinal Cases and Brief Reports, 2018, 12, 184-187.	0.6	15
77	Immunotherapy in the immunodeficient: A treatment paradox?. Annals of Oncology, 2018, 29, viii429.	1.2	0
78	CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. Lung Cancer, 2018, 115, S84.	2.0	0
79	ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi5-vi5.	1.2	0
80	Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. Annals of Oncology, 2018, 29, viii497.	1.2	12
81	Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. ELife, 2018, 7, .	6.0	99
82	CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC. Journal of Thoracic Oncology, 2018, 13, e193-e196.	1.1	29
83	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2018, 17, 2132-2145.	3.8	41
84	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future Oncology, 2018, 14, 2415-2431.	2.4	24
85	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology, 2018, 29, 1843-1852.	1.2	47
86	Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1451-1453.	5.6	54
87	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2000-2000.	1.6	17
88	A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2018, 36, 6068-6068.	1.6	4
89	Immunotherapy in metastatic melanoma: When is it safe to stop?. Journal of Clinical Oncology, 2018, 36, e21518-e21518.	1.6	0
90	CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.. Journal of Clinical Oncology, 2018, 36, TPS8586-TPS8586.	1.6	0

#	Article	IF	Citations
91	Abstract 5084: Characterizing heterogeneity in the cancer-associated fibroblast population in non-small cell lung cancer: Relating phenotype to function. , 2018, , .		2
92	Abstract LB-143: Th1/Th2 and inflammatory cytokines as biomarkers of response to ipilimumab in small cell lung cancer (SCLC) patients. , 2018, , .		0
93	Exosomal microRNAs in the lung: eliciting long-term intercellular communication?. , 2018, , .		0
94	Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). Journal of Clinical Oncology, 2017, 35, 1506-1514.	1.6	92
95	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46, 577-586.	14.3	323
96	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	27.8	1,287
97	Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nature Immunology, 2017, 18, 940-950.	14.5	407
98	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11.	28.9	968
99	Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space. Clinical Cancer Research, 2017, 23, 7641-7649.	7.0	22
100	Towards personalised medicine in lung and thymus neuroendocrine tumours. Lancet Oncology, The, 2017, 18, 1563-1565.	10.7	1
101	Evaluating the effect of immune cells on the outcome of patients with mesothelioma. British Journal of Cancer, 2017, 117, 1341-1348.	6.4	47
102	COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European Journal of Cancer, 2017, 87, 75-83.	2.8	24
103	PUB035 CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S2376.	1.1	0
104	Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).. Journal of Clinical Oncology, 2017, 35, TPS9099-TPS9099.	1.6	0
105	Abstract 2948: A distinct CD8+tumor infiltrating lymphocyte subset is associated with high TIL density, enhanced cytotoxicity and improved survival in patients with lung cancer. , 2017, , .		0
106	Transcriptomic profiling reveals M1-high tumour associated macrophages that orchestrate the adaptive Anti-tumour response in human lung cancer. , 2017, , .		0
107	Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies. PLoS ONE, 2016, 11, e0155059.	2.5	4
108	Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget, 2016, 7, 56781-56797.	1.8	86

#	Article	IF	Citations
109	Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 651-662.	4.2	91
110	Upregulated Glucose Metabolism Correlates Inversely with CD8+ T-cell Infiltration and Survival in Squamous Cell Carcinoma. Cancer Research, 2016, 76, 4136-4148.	0.9	83
111	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. Clinical Cancer Research, 2016, 22, 4827-4836.	7.0	24
112	TG4010: a vaccine with a therapeutic role in cancer. Immunotherapy, 2016, 8, 511-519.	2.0	14
113	Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. Journal of Clinical Oncology, 2016, 34, 4132-4141.	1.6	105
114	Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination. Current Topics in Microbiology and Immunology, 2016, 405, 123-143.	1.1	6
115	Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. OncoImmunology, 2016, 5, e1209615.	4.6	14
116	A plant-expressed conjugate vaccine breaks CD4⁺ tolerance and induces potent immunity against metastatic Her2⁺ breast cancer. OncoImmunology, 2016, 5, e1166323.	4.6	36
117	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology, 2016, 11, 1511-1521.	1.1	95
118	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunology, Immunotherapy, 2016, 65, 161-169.	4.2	175
119	Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. OncoImmunology, 2016, 5, e1143997.	4.6	74
120	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncology, The, 2016, 17, 212-223.	10.7	158
121	Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma. , 2016, , .		1
122	Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis. Aging, 2016, 9, 114-132.	3.1	86
123	Wilmsâ€™ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). Efficacy and Mechanism Evaluation, 2016, 3, 1-80.	0.7	7
124	LSC Abstract â€“ Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features. , 2016, , .		0
125	LSC Abstract â€“ Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features. , 2016, , .		0
126	Ipilimumab in the real world. Melanoma Research, 2015, 25, 432-442.	1.2	50

#	Article	IF	Citations
127	Plant Virus Particles Carrying Tumour Antigen Activate TLR7 and Induce High Levels of Protective Antibody. PLoS ONE, 2015, 10, e0118096.	2.5	58
128	Vaccination Expands Antigen-Specific CD4+ Memory T Cells and Mobilizes Bystander Central Memory T Cells. PLoS ONE, 2015, 10, e0136717.	2.5	23
129	Novel Approaches for Vaccination Against HPV-Induced Cancers. Current Topics in Microbiology and Immunology, 2015, 405, 33-53.	1.1	1
130	Infliximab for IPILIMUMAB-Related Colitisâ€"Letter. Clinical Cancer Research, 2015, 21, 5642-5643.	7.0	47
131	Staging and treatment of oropharyngeal cancer in the human papillomavirus era. Head and Neck, 2015, 37, 1002-1013.	2.0	49
132	Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. British Journal of Cancer, 2015, 113, 107-118.	6.4	34
133	Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. Cancer Immunology, Immunotherapy, 2015, 64, 585-598.	4.2	18
134	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunology, Immunotherapy, 2015, 64, 1021-1032.	4.2	27
135	Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study. Clinical Cancer Research, 2015, 21, 1321-1328.	7.0	81
136	Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. OncoImmunology, 2015, 4, e1040218.	4.6	39
137	Uveal Melanoma UK National Guidelines. European Journal of Cancer, 2015, 51, 2404-2412.	2.8	89
138	<scp>NYâ€ESO</scp>â€1 specific antibody and cellular responses in melanoma patients primed with <scp>NYâ€ESO</scp>â€1 protein in <scp>ISCOMATRIX</scp> and boosted with recombinant <scp>NYâ€ESO</scp>â€1 fowlpox virus. International Journal of Cancer, 2015, 136, E590-601.	5.1	46
139	An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients.. Journal of Clinical Oncology, 2015, 33, 9035-9035.	1.6	1
140	Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma.. Journal of Clinical Oncology, 2015, 33, e20000-e20000.	1.6	4
141	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. , 2015, , 471-490.		1
142	The immune response in HPV⁺oropharyngeal cancer. OncoImmunology, 2014, 3, e27254.	4.6	32
143	A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 2192-2204.	7.0	147
144	Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. Journal of the National Cancer Institute, 2014, 106, .	6.3	105

#	Article	IF	Citations
145	Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. British Journal of Cancer, 2014, 110, 489-500.	6.4	326
146	Antiâ€“CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response. Science Translational Medicine, 2014, 6, 254ra128.	12.4	325
147	Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunology, Immunotherapy, 2014, 63, 1199-1211.	4.2	30
148	Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. European Journal of Cancer, 2014, 50, 1717-1721.	2.8	12
149	The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. European Journal of Surgical Oncology, 2014, 40, 1313-1320.	1.0	135
150	The role of the reporting framework MIATA within current efforts to advance immune monitoring. Journal of Immunological Methods, 2014, 409, 6-8.	1.4	4
151	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Annals of Oncology, 2014, 25, 968-974.	1.2	68
152	Suppression of Hedgehog signalling promotes proâ€tumourigenic integrin expression and function. Journal of Pathology, 2014, 233, 196-208.	4.5	7
153	Abstract CT331: Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma. , 2014, , .		1
154	Phase I trial of ImmunoBody in melanoma patients.. Journal of Clinical Oncology, 2014, 32, 3061-3061.	1.6	2
155	FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. British Journal of Cancer, 2013, 109, 387-394.	6.4	72
156	Genetic Vaccines against Cancer. , 2013, , 223-239.		1
157	Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunology, Immunotherapy, 2013, 62, 615-627.	4.2	27
158	The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunology, Immunotherapy, 2013, 62, 489-501.	4.2	16
159	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). European Journal of Cancer, 2013, 49, 2815-2822.	2.8	45
160	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Annals of Oncology, 2013, 24, 2875-2880.	1.2	48
161	New horizons for prostate cancer: part 2. Trends in Urology & Men's Health, 2013, 4, 13-16.	0.4	0
162	New horizons for prostate cancer: part 1. Trends in Urology & Men's Health, 2013, 4, 38-40.	0.4	0

#	Article	IF	Citations
163	Abstract LB-142: A trial of agonistic anti-CD40 antibody: Biological effects in a Cancer Research UK phase I study.. , 2013, , .		1
164	A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer. Chemotherapy, 2012, 58, 257-263.	1.6	5
165	DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time. Cancer Immunology, Immunotherapy, 2012, 61, 2161-2170.	4.2	89
166	T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. Immunity, 2012, 37, 1-2.	14.3	131
167	The adaptive immune response to colorectal cancer: From the laboratory to clinical practice. European Journal of Surgical Oncology, 2012, 38, 889-896.	1.0	16
168	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health and Quality of Life Outcomes, 2012, 10, 66.	2.4	55
169	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	4.4	676
170	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 107-114.	27.0	1,976
171	Harmonization of the intracellular cytokine staining assay. Cancer Immunology, Immunotherapy, 2012, 61, 967-978.	4.2	47
172	CD8⁺ Tâ€cell crossâ€competition is governed by peptideâ€“MHC class I stability. European Journal of Immunology, 2012, 42, 256-263.	2.9	28
173	A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2012, 30, TPS8605-TPS8605.	1.6	1
174	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
175	Harmonization of Immune Biomarker Assays for Clinical Studies. Science Translational Medicine, 2011, 3, 108ps44.	12.4	87
176	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 364, 2507-2516.	27.0	6,976
177	119 Phase I dose finding study of irinotecan in combination with carboplatin in treatment naive extensive stage small cell lung cancer. Lung Cancer, 2011, 71, S41.	2.0	0
178	DNA fusion vaccines enter the clinic. Cancer Immunology, Immunotherapy, 2011, 60, 1147-1151.	4.2	21
179	DNA fusion gene vaccines induce cytotoxic Tâ€cell attack on naturally processed peptides of human prostateâ€specific membrane antigen. European Journal of Immunology, 2011, 41, 2447-2456.	2.9	15
180	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. British Journal of Cancer, 2011, 105, 353-359.	6.4	48

#	Article	IF	Citations
181	A randomised, phase II study of intetumumab, an anti-Î±v-integrin mAb, alone and with dacarbazine in stage IV melanoma. British Journal of Cancer, 2011, 105, 346-352.	6.4	108
182	T-cell immune monitoring assays to guide the development of new cancer vaccines. , 2011, , 156-166.		0
183	Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunology, Immunotherapy, 2010, 59, 863-873.	4.2	53
184	Serum is not required for ex vivo IFN-Î³ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. Cancer Immunology, Immunotherapy, 2010, 59, 619-627.	4.2	29
185	Response definition criteria for ELISPOT assays revisited. Cancer Immunology, Immunotherapy, 2010, 59, 1489-1501.	4.2	188
186	DNA vaccines against cancer come of age. Current Opinion in Immunology, 2010, 22, 264-270.	5.5	63
187	Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. International Immunology, 2010, 22, 875-887.	4.0	38
188	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 711-723.	27.0	13,065
189	Melanoma sentinel node biopsy and prediction models for relapse and overall survival. British Journal of Cancer, 2010, 103, 1229-1236.	6.4	54
190	Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 5248-5254.	1.6	65
191	The Synthesis and inâ€…vivo Evaluation of 2â€²,2â€²â€Difluoro KRN7000. ChemMedChem, 2009, 4, 329-334.	3.2	21
192	First case report of Muirâ€“Torre syndrome associated with non-small cell lung cancer. Familial Cancer, 2009, 8, 359-362.	1.9	20
193	Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. Cancer Immunology, Immunotherapy, 2009, 58, 789-800.	4.2	16
194	DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. Human Gene Therapy, 2009, 20, 1269-1278.	2.7	172
195	Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines. Clinical Lymphoma and Myeloma, 2009, 9, S23-S24.	1.4	1
196	Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood, 2009, 113, 4677-4680.	1.4	56
197	The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunology, Immunotherapy, 2008, 57, 289-302.	4.2	138
198	Synthesis and inâ€…vitro Evaluation of Î±â€GalCer Epimers. ChemMedChem, 2008, 3, 1061-1070.	3.2	33

#	Article	IF	Citations
199	Survival from melanoma of the skin in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S50-S52.	6.4	3
200	DNA vaccines: precision tools for activating effective immunity against cancer. Nature Reviews Cancer, 2008, 8, 108-120.	28.4	388
201	Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. Molecular Immunology, 2008, 45, 1567-1572.	2.2	52
202	Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet, The, 2008, 371, 1685-1694.	13.7	250
203	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, The, 2008, 372, 117-126.	13.7	620
204	Synthesis and In Vivo Evaluation of 4-Deoxy-4,4-difluoro-KRN7000. Organic Letters, 2008, 10, 4433-4436.	4.6	30
205	Taking Electroporation-Based Delivery of DNA Vaccination into Humans: A Generic Clinical Protocol. Methods in Molecular Biology, 2008, 423, 497-507.	0.9	15
206	Cancer Vaccines. , 2007, , 183-204.		4
207	C1-03: A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, S359.	1.1	4
208	Vinflunine â€“ an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. British Journal of Cancer, 2006, 94, 1383-1388.	6.4	53
209	Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?. Leukemia, 2006, 20, 530-534.	7.2	31
210	Immunoglobulin Heavy Chain Locus Events and Expression of Activation-Induced Cytidine Deaminase in Epithelial Breast Cancer Cell Lines. Cancer Research, 2006, 66, 3996-4000.	0.9	119
211	Idiotype Gene Rescue in Follicular Lymphoma. , 2005, 115, 145-172.		1
212	DNA vaccines to attack cancer. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14646-14652.	7.1	109
213	DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunological Reviews, 2004, 199, 156-180.	6.0	78
214	Dose Seeking Evaluation of a Novel Heterologous Primeboost Immunotherapy in Stage III and IV Metastatic Melanoma Patients. Journal of Immunotherapy, 2004, 27, S27.	2.4	0
215	Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 136-141.	2.2	37
216	Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. British Journal of Haematology, 2003, 120, 217-222.	2.5	56

#	Article	IF	Citations
217	Anti-idiotype vaccines. British Journal of Haematology, 2003, 123, 770-781.	2.5	27
218	Vaccine Therapy in NHL: Future Promises and Current Limitations. Leukemia and Lymphoma, 2003, 44, S85-S90.	1.3	2
219	Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood, 2002, 99, 2562-2568.	1.4	237
220	Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood, 2002, 100, 1505-1507.	1.4	105
221	The occurrence and significance of V gene mutations in B cellâ€"Derived human malignancy. Advances in Cancer Research, 2001, 83, 81-116.	5.0	95
222	The classification of lymphomas and leukemias. Chemico-Biological Interactions, 2001, 135-136, 653-664.	4.0	13
223	Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. Blood, 2000, 96, 2550-2556.	1.4	12
224	Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. Blood, 2000, 96, 2550-2556.	1.4	4
225	Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients. British Journal of Cancer, 1999, 81, 1213-1221.	6.4	12
226	Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. Immunological Reviews, 1998, 162, 247-259.	6.0	132
227	Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression. Blood, 1998, 91, 4292-4299.	1.4	133
228	Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression. Blood, 1998, 91, 4292-4299.	1.4	6
229	Absence of constitutive EGF receptor activation in ovarian cancer cell lines. British Journal of Cancer, 1996, 74, 446-452.	6.4	18
230	Histological transformation of indolent (follicular) lymphoma. Annals of Oncology, 1996, 7, 849-853.	1.2	3
231	CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors.. Journal of Clinical Oncology, 1995, 13, 1912-1921.	1.6	84
232	Expression and Function of Î²1 and Î±vÎ²3 Integrins in Ovarian Cancer. Gynecologic Oncology, 1995, 58, 216-225.	1.4	135
233	Treatment of advanced chronic lymphocytic leukemia by fludarabine. Annals of Hematology, 1991, 63, 1-4.	1.8	80
234	T _{FR} Cells Inhibit Anti-Tumor Immunity and are Responsive to Immune Checkpoint Blockade. SSRN Electronic Journal, 0, , .	0.4	1